Stacks, Blends & Protocols
CJC-1295 / Ipamorelin
A GHRH + GHRP stack built around the no-DAC version of CJC-1295 (Mod GRF 1-29) — pairing it with Ipamorelin to produce a larger, more natural pulse of your own growth hormone. Dosed before bed to mirror the body's nighttime GH rhythm. Physician-supervised for California patients.
Coming soon
Get notified when CJC-1295 / Ipamorelin launches
CJC-1295 / Ipamorelinisn't available to prescribe just yet. Leave your email and we'll let you know the moment it's ready in California — no spam.
Physician-reviewed peptide therapy, prescribed only when appropriate.
Protocol at a glance
- Route
- Subcutaneous injection
- Frequency
- Once daily before bed
- Course
- Cyclical course
Physician-reviewed. Prescribed only if appropriate after a telehealth consult — full refund if a licensed clinician determines it isn't right for you.
Why patients choose it
Why people choose the CJC / Ipamorelin stack
Two pathways, one pulse
CJC-1295 signals the pituitary through the GHRH pathway while Ipamorelin triggers GH release through the ghrelin receptor — together producing a larger, cleaner pulse than either alone.
Natural, pulsatile release
The no-DAC (Mod GRF 1-29) form is short-acting, so it mimics the body's own nighttime GH pulse instead of holding levels artificially elevated around the clock.
Selective by design
Ipamorelin is among the cleanest GHRPs — minimal impact on cortisol or prolactin and little hunger stimulation, unlike older-generation secretagogues.
Overview
What the stack is
This is a two-peptide growth-hormone stack that works your own pituitary rather than supplying growth hormone from the outside. Each peptide hits a different lever:
- CJC-1295 (no DAC / Mod GRF 1-29): a GHRH analog that tells the pituitary to release growth hormone. Because it lacks the Drug Affinity Complex, it is short-acting and produces a brief, natural pulse rather than a sustained elevation.
- Ipamorelin: a selective GHRP (ghrelin-receptor agonist, or GH secretagogue) that triggers GH release through a separate receptor and helps quiet somatostatin, the body's natural brake on GH output.
Because the two act on complementary pathways, combining them tends to amplify the GH pulse beyond what either produces on its own — which is the entire rationale behind pairing a GHRH analog with a GHRP.
Candidacy
Who it's for
This stack is generally explored by adults who want to:
- Support deeper sleep and overnight recovery
- Work on body composition — lean mass and fat — over a cyclical course
- Support their own GH output for general anti-aging goals, without exogenous HGH
- Use a more selective GHRP profile than older peptides like GHRP-2 or GHRP-6
Not FDA approved. Whether this stack is appropriate — and at what dose — is a decision to make with your prescribing physician.
What to expect
How it unfolds, week by week
01
First weeks
Dosing is typically once daily before bed so the GH pulse lands during the body's natural nighttime release window. Many people first notice changes in sleep quality.
02
Mid-course
Over a consistent course, recovery and body-composition goals are the commonly reported focus areas, building gradually rather than abruptly.
03
Ongoing
Peptide GH support is generally run cyclically. Your physician will guide course length, breaks, and whether to continue based on your response.
CJC-1295: no DAC vs. with DAC
| CJC-1295 (no DAC) | CJC-1295 with DAC | |
|---|---|---|
| Also known as | Mod GRF 1-29 | CJC-1295 DAC |
| Duration of action | Short-acting | Long-acting (extended half-life) |
| GH release pattern | Brief, natural pulse | Sustained elevation ("GH bleed") |
| Typical dosing rhythm | Timed pulses, often before bed | Less frequent, steady-state |
Comparison reflects how these forms are generally described in the peptide literature, not head-to-head clinical trials. Neither form is FDA approved.
Safety
Side effects & contraindications
GH-stimulating peptides are generally reported to be well tolerated at typical doses, but they are not without effects. The most commonly discussed:
- Injection-site redness, itching, or irritation
- Transient water retention, tingling, or numbness in the hands
- Flushing, lightheadedness, or a brief head-rush shortly after dosing
- Vivid dreams or changes in sleep, particularly with bedtime dosing
These peptides are not appropriate for everyone — active malignancy and certain other conditions are contraindications. They are not FDA approved, and quality depends on using a licensed, regulated compounding pharmacy. Review the full risk/benefit picture with your prescribing physician before starting.
FAQ
CJC / Ipamorelin questions
Related peptides
Often explored together
CJC-1295
The GHRH analog at the core of this stack — long-acting GH support, often stacked.
Learn more →Ipamorelin
Selective GH secretagogue with a clean profile — the GHRP half of the pairing.
Learn more →Sermorelin
A GHRH peptide that stimulates your own GH for sleep and recovery.
Learn more →MK-677
An oral GH secretagogue — no injection required.
Learn more →Ask about the CJC / Ipamorelin stack
Physician consult required. Not FDA approved; compounded at a licensed pharmacy only if a clinician determines it's appropriate for you. No clinic visit needed.
Check Your EligibilityCJC-1295 / Ipamorelin
Physician-reviewed